INTRODUCING NEW ANTIPERSPIRANT ACTIVE FORMULATIONS

In the U. S. the introduction of any new antiperspirant actives into the market will require a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA). These procedures will no doubt inhibit bringing new actives into the market place unless there is a strong inclination by the manufacturer to believe their new active will bring a large return from the market place. The submission of an NDA or ANDA requires a major commitment of time and capital by the manufacturer. When consumers demand new and more effective products, industry will usually respond as long as there will be the hope for a return on its investment.